{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T03:51:02Z","timestamp":1772164262820,"version":"3.50.1"},"reference-count":51,"publisher":"American Association for Cancer Research (AACR)","issue":"21","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2005,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The identification of new tumor-associated antigens (TAA) is critical for the development of effective immunotherapeutic strategies, particularly in diseases like B-cell acute lymphoblastic leukemia (B-ALL), where few target epitopes are known. To accelerate the identification of novel TAA in B-ALL, we used a combination of expression profiling and reverse immunology. We compared gene expression profiles of primary B-ALL cells with their normal counterparts, B-cell precursors. Genes differentially expressed by B-ALL cells included many previously identified as TAA in other malignancies. Within this set of overexpressed genes, we focused on those that may be functionally important to the cancer cell. The apoptosis-related molecule, BAX, was highly correlated with the ALL class distinction. Therefore, we evaluated BAX and its isoforms as potential TAA. Peptides from the isoform BAX-\u03b4 bound with high affinity to HLA-A*0201 and HLA-DR1. CD8+ CTLs specific for BAX-\u03b4 epitopes or their heteroclitic peptides could be expanded from normal donors. BAX-\u03b4\u2013specific T cells lysed peptide-pulsed targets and BAX-\u03b4\u2013expressing leukemia cells in a MHC-restricted fashion. Moreover, primary B-ALL cells were recognized by BAX-\u03b4\u2013specific CTL, indicating that this antigen is naturally processed and presented by tumor cells. This study suggests that (a) BAX-\u03b4 may serve as a widely expressed TAA in B-ALL and (b) gene expression profiling can be a generalizable tool to identify immunologic targets for cancer immunotherapy.<\/jats:p>","DOI":"10.1158\/0008-5472.can-05-1574","type":"journal-article","created":{"date-parts":[[2005,11,1]],"date-time":"2005-11-01T20:38:54Z","timestamp":1130877534000},"page":"10050-10058","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":32,"title":["Gene Expression Profiling Identifies\n                    <i>BAX-\u03b4<\/i>\n                    as a Novel Tumor Antigen in Acute Lymphoblastic Leukemia"],"prefix":"10.1158","volume":"65","author":[{"given":"Sara","family":"Maia","sequence":"first","affiliation":[{"name":"1Medical Oncology, Departments of"},{"name":"5Unit of Tumor Biology, Institute of Molecular Medicine, University of Lisbon, Portugal; and"}]},{"given":"W. Nicholas","family":"Haining","sequence":"additional","affiliation":[{"name":"2Pediatric Oncology, and"}]},{"given":"Sascha","family":"Anse\u0301n","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Departments of"}]},{"given":"Zhinan","family":"Xia","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Departments of"}]},{"given":"Scott A.","family":"Armstrong","sequence":"additional","affiliation":[{"name":"2Pediatric Oncology, and"},{"name":"4Division of Hematology\/Oncology, Children's Hospital, Boston, Massachusetts;"}]},{"given":"Nilufer P.","family":"Seth","sequence":"additional","affiliation":[{"name":"3Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Harvard Medical School;"}]},{"given":"Paolo","family":"Ghia","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Departments of"}]},{"given":"Monique L.","family":"den Boer","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Oncology\/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Rob","family":"Pieters","sequence":"additional","affiliation":[{"name":"6Department of Pediatric Oncology\/Hematology, Sophia Children's Hospital, Erasmus University Medical Center, Rotterdam, the Netherlands"}]},{"given":"Stephen E.","family":"Sallan","sequence":"additional","affiliation":[{"name":"2Pediatric Oncology, and"}]},{"given":"Lee M.","family":"Nadler","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Departments of"}]},{"given":"Angelo A.","family":"Cardoso","sequence":"additional","affiliation":[{"name":"1Medical Oncology, Departments of"}]}],"member":"1086","published-online":{"date-parts":[[2005,11,1]]},"reference":[{"key":"2022061706304076500_B1","doi-asserted-by":"crossref","unstructured":"Yee C, Gilbert MJ, Riddell SR, et al. Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol\u20081996; 157: 4079\u201386.","DOI":"10.4049\/jimmunol.157.9.4079"},{"key":"2022061706304076500_B2","doi-asserted-by":"crossref","unstructured":"Wang RF, Johnston SL, Zeng G, Topalian SL, Schwartzentruber DJ, Rosenberg SA. A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. J Immunol\u20081998; 161: 3598\u2013606.","DOI":"10.4049\/jimmunol.161.7.3596"},{"key":"2022061706304076500_B3","doi-asserted-by":"crossref","unstructured":"Bonnet D, Warren EH, Greenberg PD, Dick JE, Riddell SR. CD8(+) minor histocompatibility antigen-specific cytotoxic T lymphocyte clones eliminate human acute myeloid leukemia stem cells. Proc Natl Acad Sci U S A\u20081999; 96: 8639\u201344.","DOI":"10.1073\/pnas.96.15.8639"},{"key":"2022061706304076500_B4","doi-asserted-by":"crossref","unstructured":"Scardino A, Alves P, Gross DA, et al. Identification of HER-2\/neu immunogenic epitopes presented by renal cell carcinoma and other human epithelial tumors. Eur J Immunol\u20082001; 31: 3261\u201370.","DOI":"10.1002\/1521-4141(200111)31:11<3261::AID-IMMU3261>3.0.CO;2-4"},{"key":"2022061706304076500_B5","doi-asserted-by":"crossref","unstructured":"Cardoso AA, Seamon MJ, Afonso HM, et al. Ex-vivo generation of anti-pre-B leukemia specific autologous cytolytic T cells. Blood\u20081997; 90: 549\u201361.","DOI":"10.1182\/blood.V90.2.549"},{"key":"2022061706304076500_B6","doi-asserted-by":"crossref","unstructured":"Yotnda P, Garcia F, Peuchmaur M, et al. Cytotoxic T cell response against the chimeric ETV6-AML1 protein in childhood acute lymphoblastic leukemia. J Clin Invest\u20081998; 102: 455\u201362.","DOI":"10.1172\/JCI3126"},{"key":"2022061706304076500_B7","doi-asserted-by":"crossref","unstructured":"Cardoso AA, Veiga JP, Ghia P, et al. Adoptive T-cell therapy for B-cell acute lymphoblastic leukemia: preclinical studies. Blood\u20081999; 94: 3531\u201340.","DOI":"10.1182\/blood.V94.10.3531.422k14_3531_3540"},{"key":"2022061706304076500_B8","doi-asserted-by":"crossref","unstructured":"Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood\u20081999; 93: 2336\u201341.","DOI":"10.1182\/blood.V93.7.2336.407k26_2336_2341"},{"key":"2022061706304076500_B9","doi-asserted-by":"crossref","unstructured":"Montagna D, Maccario R, Locatelli F, et al. Ex vivo priming for long-term maintenance of antileukemia human cytotoxic T cells suggests a general procedure for adoptive immunotherapy. Blood\u20082001; 98: 3359\u201366.","DOI":"10.1182\/blood.V98.12.3359"},{"key":"2022061706304076500_B10","doi-asserted-by":"crossref","unstructured":"Dolstra H, Fredrix H, Maas F, et al. A human minor histocompatibility antigen specific for B cell acute lymphoblastic leukemia. J Exp Med\u20081999; 189: 301\u20138.","DOI":"10.1084\/jem.189.2.301"},{"key":"2022061706304076500_B11","doi-asserted-by":"crossref","unstructured":"Ohminami H, Yasukawa M, Fujita S. HLA class I-restricted lysis of leukemia cells by a CD8(+) cytotoxic T-lymphocyte clone specific for WT1 peptide. Blood\u20082000; 95: 286\u201393.","DOI":"10.1182\/blood.V95.1.286.001k48_286_293"},{"key":"2022061706304076500_B12","unstructured":"Muller MR, Grunebach F, Kayser K, et al. Expression of HER-2\/neu on acute lymphoblastic leukemias: implications for the development of immunotherapeutic approaches. Clin Cancer Res\u20082003; 9: 3448\u201353."},{"key":"2022061706304076500_B13","doi-asserted-by":"crossref","unstructured":"Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PD. Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell\u20082003; 3: 431\u20137.","DOI":"10.1016\/S1535-6108(03)00113-2"},{"key":"2022061706304076500_B14","doi-asserted-by":"crossref","unstructured":"Golub TR, Slonim DK, Tamayo P, et al. Molecular classification of cancer: class discovery and class prediction by gene expression monitoring. Science\u20081999; 286: 531\u20137.","DOI":"10.1126\/science.286.5439.531"},{"key":"2022061706304076500_B15","doi-asserted-by":"crossref","unstructured":"Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. Nat Genet\u20082002; 30: 41\u20137.","DOI":"10.1038\/ng765"},{"key":"2022061706304076500_B16","doi-asserted-by":"crossref","unstructured":"Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol\u20081994; 152: 163\u201375.","DOI":"10.4049\/jimmunol.152.1.163"},{"key":"2022061706304076500_B17","doi-asserted-by":"crossref","unstructured":"Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanovic S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics\u20081999; 50: 213\u20139.","DOI":"10.1007\/s002510050595"},{"key":"2022061706304076500_B18","doi-asserted-by":"crossref","unstructured":"Day CL, Seth NP, Lucas M, et al. Ex vivo analysis of human memory CD4 T cells specific for hepatitis C virus using MHC class II tetramers. J Clin Invest\u20082003; 112: 831\u201342.","DOI":"10.1172\/JCI200318509"},{"key":"2022061706304076500_B19","doi-asserted-by":"crossref","unstructured":"Schultze JL, Michalak S, Seamon MJ, et al. CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest\u20081997; 100: 2757\u201365.","DOI":"10.1172\/JCI119822"},{"key":"2022061706304076500_B20","doi-asserted-by":"crossref","unstructured":"Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell\u20082002; 1: 133\u201343.","DOI":"10.1016\/S1535-6108(02)00032-6"},{"key":"2022061706304076500_B21","unstructured":"Shurtleff SA, Buijs A, Behm FG, et al. TEL\/AML1 fusion resulting from a cryptic t(12;21) is the most common genetic lesion in pediatric ALL and defines a subgroup of patients with an excellent prognosis. Leukemia\u20081995; 9: 1985\u20139."},{"key":"2022061706304076500_B22","doi-asserted-by":"crossref","unstructured":"Schmollinger JC, Vonderheide RH, Hoar KM, et al. Melanoma inhibitor of apoptosis protein (ML-IAP) is a target for immune-mediated tumor destruction. Proc Natl Acad Sci U S A\u20082003; 100: 3398\u2013403.","DOI":"10.1073\/pnas.0530311100"},{"key":"2022061706304076500_B23","doi-asserted-by":"crossref","unstructured":"Bilsborough J, Van Pel A, Uyttenhove C, Boon T, Van den Eynde BJ. Identification of a second major tumor-specific antigen recognized by CTLs on mouse mastocytoma P815. J Immunol\u20081999; 162: 3534\u201340.","DOI":"10.4049\/jimmunol.162.6.3534"},{"key":"2022061706304076500_B24","doi-asserted-by":"crossref","unstructured":"Li J, Li W, Liang S, et al. Recombinant CD63\/ME491\/neuroglandular\/NKI\/C-3 antigen inhibits growth of established tumors in transgenic mice. J Immunol\u20082003; 171: 2922\u20139.","DOI":"10.4049\/jimmunol.171.6.2922"},{"key":"2022061706304076500_B25","doi-asserted-by":"crossref","unstructured":"Sanchez-Garcia I, Grutz G. Tumorigenic activity of the BCR-ABL oncogenes is mediated by BCL2. Proc Natl Acad Sci U S A\u20081995; 92: 5287\u201391.","DOI":"10.1073\/pnas.92.12.5287"},{"key":"2022061706304076500_B26","doi-asserted-by":"crossref","unstructured":"Smith KS, Rhee JW, Cleary ML. Transformation of bone marrow B-cell progenitors by E2a-Hlf requires coexpression of Bcl-2. Mol Cell Biol\u20082002; 22: 7678\u201387.","DOI":"10.1128\/MCB.22.21.7678-7688.2002"},{"key":"2022061706304076500_B27","doi-asserted-by":"crossref","unstructured":"Swanson PJ, Kuslak SL, Fang W, et al. Fatal acute lymphoblastic leukemia in mice transgenic for B cell-restricted bcl-xL and c-myc. J Immunol\u20082004; 172: 6684\u201391.","DOI":"10.4049\/jimmunol.172.11.6684"},{"key":"2022061706304076500_B28","unstructured":"Schmitz M, Diestelkoetter P, Weigle B, et al. Generation of survivin-specific CD8+ T effector cells by dendritic cells pulsed with protein or selected peptides. Cancer Res\u20082000; 60: 4845\u20139."},{"key":"2022061706304076500_B29","doi-asserted-by":"crossref","unstructured":"Andersen MH, Svane IM, Kvistborg P, et al. Immunogenicity of Bcl-2 in patients with cancer. Blood\u20082005; 105: 728\u201334.","DOI":"10.1182\/blood-2004-07-2548"},{"key":"2022061706304076500_B30","doi-asserted-by":"crossref","unstructured":"Tourdot S, Scardino A, Saloustrou E, et al. A general strategy to enhance immunogenicity of low-affinity HLA-A2. 1-associated peptides: implication in the identification of cryptic tumor epitopes. Eur J Immunol\u20082000; 30: 3411\u201321.","DOI":"10.1002\/1521-4141(2000012)30:12<3411::AID-IMMU3411>3.0.CO;2-R"},{"key":"2022061706304076500_B31","doi-asserted-by":"crossref","unstructured":"Zweerink HJ, Gammon MC, Utz U, et al. Presentation of endogenous peptides to MHC class I-restricted cytotoxic T lymphocytes in transport deletion mutant T2 cells. J Immunol\u20081993; 150: 1763\u201371.","DOI":"10.4049\/jimmunol.150.5.1763"},{"key":"2022061706304076500_B32","doi-asserted-by":"crossref","unstructured":"Schultze JL, Vonderheide RH. From cancer genomics to cancer immunotherapy: toward second-generation tumor antigens. Trends Immunol\u20082001; 22: 516\u201323.","DOI":"10.1016\/S1471-4906(01)02015-4"},{"key":"2022061706304076500_B33","doi-asserted-by":"crossref","unstructured":"Ebert BL, Golub TR. Genomic approaches to hematologic malignancies. Blood\u20082004; 104: 923\u201332.","DOI":"10.1182\/blood-2004-01-0274"},{"key":"2022061706304076500_B34","doi-asserted-by":"crossref","unstructured":"Apte SS, Mattei MG, Olsen BR. Mapping of the human BAX gene to chromosome 19q13.3-q13.4 and isolation of a novel alternatively spliced transcript, BAX \u03b4. Genomics\u20081995; 26: 592\u20134.","DOI":"10.1016\/0888-7543(95)80180-T"},{"key":"2022061706304076500_B35","doi-asserted-by":"crossref","unstructured":"Zha H, Aime-Sempe C, Sato T, Reed JC. Proapoptotic protein Bax heterodimerizes with Bcl-2 and homodimerizes with Bax via a novel domain (BH3) distinct from BH1 and BH2. J Biol Chem\u20081996; 271: 7440\u20134.","DOI":"10.1074\/jbc.271.13.7440"},{"key":"2022061706304076500_B36","doi-asserted-by":"crossref","unstructured":"McKenna SL, Cotter TG. Functional aspects of apoptosis in hematopoiesis and consequences of failure. Adv Cancer Res\u20081997; 71: 121\u201364.","DOI":"10.1016\/S0065-230X(08)60098-6"},{"key":"2022061706304076500_B37","doi-asserted-by":"crossref","unstructured":"Rosenfeld C, Cheever MA, Gaiger A. WT1 in acute leukemia, chronic myelogenous leukemia and myelodysplastic syndrome: therapeutic potential of WT1 targeted therapies. Leukemia\u20082003; 17: 1301\u201312.","DOI":"10.1038\/sj.leu.2402988"},{"key":"2022061706304076500_B38","doi-asserted-by":"crossref","unstructured":"Kim NW, Piatyszek MA, Prowse KR, et al. Specific association of human telomerase activity with immortal cells and cancer. Science\u20081994; 266: 2011\u20135.","DOI":"10.1126\/science.7605428"},{"key":"2022061706304076500_B39","unstructured":"Brossart P, Schneider A, Dill P, et al. The epithelial tumor antigen MUC1 is expressed in hematological malignancies and is recognized by MUC1-specific cytotoxic T-lymphocytes. Cancer Res\u20082001; 61: 6846\u201350."},{"key":"2022061706304076500_B40","doi-asserted-by":"crossref","unstructured":"Steinbach D, Viehmann S, Zintl F, Gruhn B. PRAME gene expression in childhood acute lymphoblastic leukemia. Cancer Genet Cytogenet\u20082002; 138: 89\u201391.","DOI":"10.1016\/S0165-4608(02)00582-4"},{"key":"2022061706304076500_B41","doi-asserted-by":"crossref","unstructured":"Haining WN, Cardoso AA, Keczkemethy HL, et al. Failure to define window of time for autologous tumor vaccination in patients with newly diagnosed or relapsed acute lymphoblastic leukemia. Exp Hematol\u20082005; 3: 286\u201394.","DOI":"10.1016\/j.exphem.2004.12.001"},{"key":"2022061706304076500_B42","doi-asserted-by":"crossref","unstructured":"Todisco E, Gaipa G, Biagi E, et al. CD40 ligand-stimulated B cell precursor leukemic cells elicit interferon-\u03b3 production by autologous bone marrow T cells in childhood acute lymphoblastic leukemia. Leukemia\u20082002; 16: 2046\u201354.","DOI":"10.1038\/sj.leu.2402672"},{"key":"2022061706304076500_B43","doi-asserted-by":"crossref","unstructured":"Bollard CM, Aguilar L, Straathof KC, et al. Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's disease. J Exp Med\u20082004; 200: 1623\u201333.","DOI":"10.1084\/jem.20040890"},{"key":"2022061706304076500_B44","doi-asserted-by":"crossref","unstructured":"Walter EA, Greenberg PD, Gilbert MJ, et al. Reconstitution of cellular immunity against cytomegalovirus in recipients of allogeneic bone marrow by transfer of T-cell clones from the donor. N Engl J Med\u20081995; 333: 1038\u201344.","DOI":"10.1056\/NEJM199510193331603"},{"key":"2022061706304076500_B45","doi-asserted-by":"crossref","unstructured":"Robbins PF, Dudley ME, Wunderlich J, et al. Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy. J Immunol\u20082004; 173: 7125\u201330.","DOI":"10.4049\/jimmunol.173.12.7125"},{"key":"2022061706304076500_B46","doi-asserted-by":"crossref","unstructured":"Rooney CM, Smith CA, Ng CY, et al. Use of gene-modified virus-specific T lymphocytes to control Epstein-Barr-virus-related lymphoproliferation. Lancet\u20081995; 345: 9\u201313.","DOI":"10.1016\/S0140-6736(95)91150-2"},{"key":"2022061706304076500_B47","doi-asserted-by":"crossref","unstructured":"Dudley ME, Wunderlich JR, Robbins PF, et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science\u20082002; 298: 850\u20134.","DOI":"10.1126\/science.1076514"},{"key":"2022061706304076500_B48","doi-asserted-by":"crossref","unstructured":"Smyth MJ, Godfrey DI, Trapani JA. A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol\u20082001; 2: 293\u20139.","DOI":"10.1038\/86297"},{"key":"2022061706304076500_B49","doi-asserted-by":"crossref","unstructured":"Toes RE, Hoeben RC, van der Voort EI, et al. Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion. Proc Natl Acad Sci U S A\u20081997; 94: 14660\u20135.","DOI":"10.1073\/pnas.94.26.14660"},{"key":"2022061706304076500_B50","unstructured":"Smith SG, Patel PM, Porte J, Selby PJ, Jackson AM. Human dendritic cells genetically engineered to express a melanoma polyepitope DNA vaccine induce multiple cytotoxic T-cell responses. Clin Cancer Res\u20082001; 7: 4253\u201361."},{"key":"2022061706304076500_B51","doi-asserted-by":"crossref","unstructured":"Dutoit V, Taub RN, Papadopoulos KP, et al. Multiepitope CD8(+) T cell response to a NY-ESO-1 peptide vaccine results in imprecise tumor targeting. J Clin Invest\u20082002; 110: 1813\u201322.","DOI":"10.1172\/JCI16428"}],"container-title":["Cancer Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/21\/10050\/2866092\/10050-10058.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerres\/article-pdf\/65\/21\/10050\/2866092\/10050-10058.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,5]],"date-time":"2023-05-05T03:36:41Z","timestamp":1683257801000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerres\/article\/65\/21\/10050\/657445\/Gene-Expression-Profiling-Identifies-BAX-as-a"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,11,1]]},"references-count":51,"journal-issue":{"issue":"21","published-online":{"date-parts":[[2005,11,1]]},"published-print":{"date-parts":[[2005,11,1]]}},"URL":"https:\/\/doi.org\/10.1158\/0008-5472.can-05-1574","relation":{"is-supplemented-by":[{"id-type":"doi","id":"10.1158\/0008-5472.22367648.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.22367648","asserted-by":"object"}],"has-preprint":[{"id-type":"doi","id":"10.1158\/0008-5472.c.6495635","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/0008-5472.c.6495635.v1","asserted-by":"object"}]},"ISSN":["0008-5472","1538-7445"],"issn-type":[{"value":"0008-5472","type":"print"},{"value":"1538-7445","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,11,1]]}}}